1. Home
  2. VTSI vs BOLD Comparison

VTSI vs BOLD Comparison

Compare VTSI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

HOLD

Current Price

$3.15

Market Cap

51.0M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.51

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTSI
BOLD
Founded
1993
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
57.5M
IPO Year
1999
2024

Fundamental Metrics

Financial Performance
Metric
VTSI
BOLD
Price
$3.15
$2.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$4.00
AVG Volume (30 Days)
49.6K
2.3M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$185,971.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$27.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$0.96
52 Week High
$7.47
$2.79

Technical Indicators

Market Signals
Indicator
VTSI
BOLD
Relative Strength Index (RSI) 37.76 76.94
Support Level N/A $1.08
Resistance Level $3.60 $2.79
Average True Range (ATR) 0.15 0.14
MACD 0.01 0.08
Stochastic Oscillator 10.38 79.21

Price Performance

Historical Comparison
VTSI
BOLD

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: